AI assistant
Beta Bionics, Inc. — Director's Dealing 2025
Feb 4, 2025
32351_dirs_2025-02-03_82020049-6a3f-4008-afd2-3d1686a123a6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-31
Reporting Person: Feider Stephen (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-31 | Employee Stock Option (right to buy) | $7.51 | A | 166542 | Acquired | 2032-07-31 | Common Stock (166542) | Direct |
| 2025-01-31 | Employee Stock Option (right to buy) | $5.10 | A | 109695 | Acquired | 2033-09-13 | Common Stock (109695) | Direct |
| 2025-01-31 | Employee Stock Option (right to buy) | $17 | A | 186203 | Acquired | 2035-01-28 | Common Stock (186203) | Direct |
Footnotes
F1: One-fourth of the shares subject to this option shall vest one year after August 1, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
F3: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
F4: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.